Background: Molecular biomarkers have the potential to improve the current state of early lung cancer detection. The goal of this project was to develop a policy statement that provides guidance about the level of evidence required to determine that a molecular biomarker, used to support early lung cancer detection, is appropriate for clinical use.
Contents
A new lung cancer biomarker will be clinically useful if it fulfills an unmet clinical need or provides an advantage over standard practice (e.g., more accurate, simpler to use, provides results more rapidly, lowers costs). The ultimate measure of lung cancer biomarker performance is whether and how the result affects clinical management decisions and clinical outcomes (1) . Even biomarkers that are sensitive and specific enough to be considered accurate by most clinicians may not impact clinical care, or may adversely impact clinical care (e.g., Table 1 ).
The goal of this project was to develop a policy statement that provides guidance about the evidence required to determine whether a molecular biomarker for the early detection of lung cancer is appropriate for clinical use.
Methods
During the first stage of the project, the project co-chairs (P.J.M. and C.R.S.) developed an overview of biomarker development principles and the current state of lung cancer risk prediction, early detection, and diagnosis, as well as a survey with questions related to each of the phases of biomarker development. A conference call was held to introduce the project to the steering committee. The documents were then circulated to the steering committee for review. The survey was completed and returned by 11 of the 12 steering committee members, and the results were collated. The survey responses were used to generate discussion questions.
The project ad hoc steering committee was selected to include individuals with an interest in lung cancer biomarker development and expertise in the various phases of biomarker development. Representatives of American Thoracic Society international partner societies (Chinese Thoracic Society, European Respiratory Society, and Japanese Respiratory Society) and the U.S. Food and Drug Administration were invited to participate on the steering committee. Potential conflicts of interest were disclosed and managed in accordance with the policies and procedures of the American Thoracic Society. The committee had a faceto-face meeting on May 13, 2016 at the annual international conference of the American Thoracic Society. The meeting included a presentation from a patient advocate, and presentations related to the phases of biomarker development. The formal presentations were followed by discussions guided by questions generated from the survey responses (see below).
Separately, the steering committee reviewed definitions, reporting considerations, target conditions, target populations, reference standards, and the potential impact of true-positive/-negative and false-positive/-negative results within each potential clinical application. A draft of the current document was developed by Test result positive  9  99  108  Test result negative  1  891  892  Total  10  990  1,000 If a molecular biomarker is 90% sensitive and 90% specific for the detection of a malignant lung nodule, it would generally be considered an accurate test. If applied to a population of patients with lung nodules with a 1% probability of malignancy (e.g., solid nodules 4-8 mm in diameter), 92% of all positive test results would be false positive, potentially leading to more aggressive evaluation of many patients without lung cancer, with physical, social, and behavioral consequences.
the project co-chairs and then circulated for review. The draft was modified several times, based on written feedback from the project steering committee and on feedback received during a phone conference. Relevant definitions and additional references are presented in Appendices 1 and 2.
Background Clinical Utility Phase of Biomarker Development
The clinical utility phase of biomarker development follows successful completion of biomarker discovery, analytical validation of the biomarker assay, and clinical validation of the accuracy of the biomarker ( Figure 1 The measurement and interpretation of cost-effectiveness is complex. It requires accurate estimates of the net cost of implementing a biomarker for a given outcome. CEA is only relevant if clinical utility has been proven (e.g., reduced mortality in a cancer screening trial). CEA uses data from published studies to determine measures such as sensitivity, specificity, and disease prevalence. It is imperative that CEA be measured in the correct clinical context across diverse ethnic and social groups, and be compared with accepted clinical practices (incremental costeffectiveness ratio). It is difficult to compare the cost-effectiveness of one biomarker or intervention with another if different measures are used. For that reason, uniform measurement and reporting of costeffectiveness using quality-adjusted life-years (QALYs) or similar measures are recommended. For example, sensitivity analyses should be performed and costeffectiveness acceptability curves published to account for variability in the costs and outcomes by location, population, and clinical context (7) (8) (9) (10) (11) .
Results
The following questions were discussed, with group consensus summarized after each question: The project steering committee recognized that biomarkers within a given biomarker category may have more than one clinical use ( Table 2) . As this statement is intended to be a guide to help determine when a molecular biomarker is ready for clinical use for the early detection of lung cancer, the committee determined that it was best to organize our comments by the most relevant clinical applications (lung cancer screening and lung nodule evaluation). 3. a. What amount of time before a diagnosis of lung cancer would be considered adequate to separate a risk prediction biomarker from a cancer detection biomarker? b. Should a biomarker of risk of "being diagnosed" with lung cancer or of "dying of" lung cancer be defined? c. Is "being diagnosed" with lung cancer or "developing" lung cancer a better way to define a risk prediction biomarker?
The steering committee recognized that it is difficult to distinguish between a biomarker that predicts the risk of lung cancer developing over a period of time and a cancer detection biomarker. A biomarker whose intended use is to determine the risk of developing lung cancer, may identify lung cancer that is present but cannot be detected by currently available means. To be defined as a biomarker of risk, the reference standard available at the time the biomarker sample is collected should be used to exclude the presence of lung cancer. A time interval between when the biomarker sample was collected and lung cancer was identified may be established to add further reassurance that the cancer was not present at the time of sample collection, or the accuracy of the biomarker at various time intervals from collection to diagnosis can be assessed.
There are different arguments for and against defining a risk prediction biomarker as one that would predict the risk of developing, being diagnosed with, or dying of lung cancer. The accuracy of the biomarker would be influenced by the definition. Not all lung cancers will be diagnosed, making it impossible to confirm how many cancers develop (although statistical models can be used to estimate the number). A definition that requires death from lung cancer would exclude overdiagnosed cancers but would not be able to address the influence of treatment or competing risks of death on the accuracy of the biomarker. The steering committee concluded that it is more important that the definition of a risk prediction biomarker be clearly described when it is used or studied than it is to mandate a single standardized definition. A general definition is provided in Table 2. 4. a. How do we define early detection of lung cancer? b. Should we add language about potential lethality of the cancer? Should biomarkers applied for the early detection of lung cancer be considered only for asymptomatic individuals or include a group with symptoms undergoing evaluation?
The World Health Organization describes two components of early detection of cancer (12) . The first is early diagnosis through prompt action when symptoms or signs of cancer are present. The second is through screening someone at risk for having cancer but who is free of symptoms or signs. The steering committee recognized these and other acceptable definitions, such as diagnosing lung cancer at a stage that is more amenable to successful treatment (e.g., stage I, localized or locoregional) or AMERICAN THORACIC SOCIETY DOCUMENTS e18 diagnosing lung cancer earlier than it would otherwise have been diagnosed. There was substantial debate about whether the definition of early detection of lung cancer should include lung cancer diagnosis when symptoms or signs of cancer are present, or only include lung cancer diagnosis in asymptomatic individuals. A consensus definition of early detection of lung cancer was not developed. We concluded that it is more important that the definition of early detection be clearly described within studies assessing the individual biomarkers, with distinction between biomarker-detected lung cancer in patients with and without symptoms. To be clinically useful, an early detection biomarker should detect lung cancer that could be lethal if not detected and treated early. This should be considered when interpreting studies of early detection biomarkers. For the reasons described in question 3 above, the steering committee did not believe it was practical to mandate that lethality of the cancer be included in the definition of an early detection biomarker. To justify the investment required to complete the clinical utility phase of biomarker development, the steering committee members agreed that it would be helpful to provide guidance about the minimal accuracy, as assessed in the clinical validation phase, that could lead to a positive clinical impact. This minimal accuracy would vary by clinical application, and be guided by an understanding of the consequences of true and false results (13) . Several methods have been described to assist with the estimate of minimal accuracy, such as calculation of the optimal slope of the receiver operating characteristic curve (14) . Here we describe a formula to help with this estimate (15) . Biomarkers are frequently optimized for sensitivity or specificity based on their intended clinical application. For tests where a positive biomarker result leads to an action whereas a negative biomarker result is associated with standard of care for the population, the formula states: sensitivity/(1 2 specificity) > [(1 2 prevalence)/prevalence] 3 harm/benefit, where harm/benefit is the ratio of the net harm of a falsely positive test result to the net benefit of a true-positive test result.
For tests where a negative result leads to an action other than standard of care for the population, the formula states: specificity/(1 2 sensitivity) > [prevalence/(1 2 prevalence)] 3 harm/benefit, where harm/benefit is the ratio of the net harm of a falsely negative test result to the net benefit of a truenegative test result.
Sensitivity/(1 2 specificity) is known as the positive likelihood ratio, and specificity/(1 2 sensitivity) is 1 divided by the negative likelihood ratio. Prevalence refers to the percentage of cases in the intended use population. The harm/benefit ratio in the formulas can be articulated in one of two ways: a. 1/N, where in the first scenario N is the maximum number of control subjects testing positive that is tolerated to benefit one case subject testing positive (or in the second formula, the maximum number of case subjects testing negative that is worth the benefit of one control subject testing negative). For example, if the biomarker is used as an upfront lung (1 2 R) , where R is the risk threshold above which procedures consequent to positive testing, and below which avoidance of procedures consequent to negative testing, seem worthwhile. For example, when evaluating a lung nodule with a biomarker, the risk threshold R could be the probability or risk that a lung nodule is malignant at which one is indifferent to choosing surveillance imaging versus active investigation.
It is important to compare and combine biomarker accuracies with testing available in current practice. The accuracy required to impact clinical care is dependent on the needs within a clinical application and the potential consequences of the results. This will vary by clinical application, highlighting the need to judge the utility of the biomarker on a fit-for-purpose basis.
6. a. Should we include guidance about cost-effectiveness or leave this to society and regulators to decide? b. Is affordability an adequate outcome at the expense of accuracy?
It is important that cost-effectiveness analysis be performed and reported within each clinical application. Ideally, a third-party independent analysis would be performed to avoid the potential for bias. The steering committee members decided that defining a threshold of costeffectiveness that is acceptable to society is beyond the scope of this statement.
7. Should we include guidance about the components of study design and details of study results that should be reported for all phases of biomarker development?
As the focus of this project is on clinical utility of early detection biomarkers, the steering committee agreed that we should suggest components of the study design and details of the study results that should be reported for the phases of biomarker development that most directly influence the interpretation of clinical utility. This includes clinical validation, clinical utility, and cost-effectiveness (Table 3) .
Discussion: Clinical Applications of Molecular Biomarkers for the Early Detection of Lung Cancer
The goal of this project is to provide guidance about the evidence required to determine that a molecular biomarker for early lung cancer detection is ready for clinical use. The most relevant clinical applications of a biomarker for the early detection of lung cancer are the selection of individuals for further lung cancer screening, and assistance with the characterization and management of lung nodules. For these two clinical applications, we discuss currently accepted practice, and then outline (1) the potential clinical utility and category of the biomarker, (2) the potential impact of applying the biomarker, (3) the level of evidence and accuracy that could support assessment of clinical utility, and (4) the level of evidence required to confirm the clinical utility of the biomarker.
Lung Cancer Screening
Current state. The National Lung Screening Trial (NLST) randomized more than 53,000 people at high risk of developing lung cancer (ages, 55-74 yr; active or former smokers of at least 30 pack-years who had smoked within the past 15 yr) to receive a baseline and two annual low-radiation-dose chest CT scans or a baseline and two annual chest radiographs. Fewer people in the chest CT arm died of lung cancer (16) . Several potential harms from lung cancer screening have been described. For example, lung nodules are frequently identified. Although usually benign, their identification leads to patient distress, additional imaging, and nonsurgical and surgical biopsies, all with potential complications. Radiation exposure during chest imaging and the evaluation and treatment of overdiagnosed lung cancers are other harms that have been reported (17, 18) .
Multiple models exist to help estimate the risk of developing lung cancer (Table 4 ) (19) (20) (21) (22) (23) (24) . One model, PLCO (Prostate, Lung, Colorectal, and Ovarian Screening Trial, 2012), was evaluated in comparison with the NLST criteria, showing marginally improved sensitivity with similar specificity for identifying patients with lung cancer (25) . At this time, it is not clear whether having a risk of developing lung cancer equal to that of the cohort obtained using NLST criteria, based on factors included in a risk model, will result in a similar balance of benefit to harm from lung cancer screening.
The cost-effectiveness of lung cancer screening by low-dose CT, based on the NLST data, was estimated to be $81,000 per QALY gained, which is within the range typically considered cost-effective. Sensitivity analysis showed a range of $32,000-$615,000. Factors associated with this variability included the patient's lung cancer risk, sex, age, and smoking status at the time of screening (26) .
Potential clinical utility of a molecular biomarker applied as an initial test in a screening context. A clinically useful molecular biomarker applied as the initial test for lung cancer screening may improve the balance of benefit to harm of lung cancer screening by identifying those most likely to benefit from screening while minimizing exposure to harm among those least likely to benefit.
Category of biomarker. A molecular biomarker applied as an initial test in a screening context would be either a risk prediction or cancer detection biomarker. (27) . This can represent an accepted risk threshold level. If we set a goal of expanding the eligible population for screening to include a lower risk population, such as those with Table 6 .
Evidence required for a molecular biomarker to be considered clinically useful in the context of lung cancer screening. To be considered clinically useful, a molecular biomarker used to identify patients eligible for lung cancer screening must lead to:
d Fewer lung cancer deaths in the population tested compared with the current standard of care for that population, without substantially increasing harms and expense, or d A similar number of lung cancer deaths in the population tested compared with the current standard of care for that population, with fewer harms or less expense.
It can be difficult, time consuming, and resource intensive to perform studies capable of proving clinical utility. Examples of study designs that could be used to obtain the above outcomes include the following (Figure 2 ):
d A molecular biomarker is measured retrospectively from archived samples obtained prospectively during a controlled trial of lung cancer screening. d A molecular biomarker is measured prospectively during a controlled trial of lung cancer screening in which the biomarker result is not used to guide which lung cancer screening intervention the patient is assigned to. d A molecular biomarker is measured prospectively, and the result is used to stratify patients into two arms (positive result and negative result). Patients in each arm are then randomized to one of two screening interventions (one of which may be standard of care for the population).
Note: These designs can be incorporated into any controlled trial of lung cancer screening.
ENRICHMENT.
d A molecular biomarker is measured prospectively, and the result is used to stratify patients into two arms (positive result and negative result). Patients in the biomarker-positive arm are then randomized to one of two screening interventions (one of which may be standard of care for the population).
Patients in the biomarker-negative arm receive standard of care for the study population.
Note: This design may be preferred in study cohorts at very low risk of having lung cancer as it may not be practical to randomize those with a negative biomarker result to a screening intervention other than standard of care.
BIOMARKER STRATEGY.
d A prospective controlled trial in which study subjects are randomized to a study arm where the receipt of the screening intervention is based on the result of a molecular biomarker, and a second arm where subjects receive standard of care for the study population. Figure 2 . Examples of study designs capable of assessing the study outcomes of interest in a trial assessing the clinical utility of a lung cancer screening molecular biomarker. "Lung cancer screening intervention" may represent low-dose computed tomography screening, no screening, standard of care for the population, or another screening test. Biomarker stratified: (A) Biomarker (orange circle) is measured retrospectively from prospectively collected archived samples, or is measured prospectively, but the results are not used to determine the study arm. (B) Biomarker (blue circle) is measured prospectively, and the result is used to stratify patients. Ideally, both biomarker-positive and biomarker-negative patients are randomized to one of the screening interventions. Enrichment: (C) In populations at very low risk of having lung cancer it may not be practical to randomize those in the biomarker-negative arm to a screening intervention other than standard of care for the studied population. Biomarker strategy: (D) The study population is randomized to a biomarker (blue circle)-strategy arm, where the receipt of the screening intervention is based on the biomarker results, and an arm where all receive standard of care for the study population.
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Note: This design can be used in currently eligible or ineligible populations. It is less efficient than biomarker-stratified designs and cannot address whether the screening intervention is effective regardless of biomarker status.
Cost-effectiveness considerations for a lung cancer screening biomarker.
d It is important to consider whether the additional costs of the test would result in enough benefit to prove cost-effective (e.g., based on QALYs or incremental cost-effectiveness ratio) in comparison with currently practiced screening strategies alone within the intended use population. d To be cost-effective, a test applied to a large population with a relatively low incidence of lung cancer (such as in screening) would need to be relatively inexpensive.
Lung Nodule Evaluation
Current state. Lung nodule management algorithms, based on the probability of malignancy, are available for solid subcentimeter nodules, solid larger (1-to 3-cm) nodules, and for subsolid nodules (28) (29) (30) (31) . Solid subcentimeter lung nodules have a low probability of being malignant and are difficult to characterize by additional imaging or nonsurgical biopsies. Thus, surveillance imaging is the most appropriate management strategy. The interval and duration of surveillance are based on the size of the nodule.
Solid nodules larger than 1 cm have a higher probability of malignancy. Lung nodule risk calculators have been developed for this group (32, 33) . Additional imaging and nonsurgical biopsies are more helpful for characterizing these nodules as benign or malignant. Very low-risk nodules enter a surveillance strategy, low-to moderate-risk nodules can be further characterized by PET imaging and/or nonsurgical biopsy, whereas high-risk nodules may proceed directly to surgical resection. PET imaging has a sensitivity for malignancy near 90%, whereas the specificity is lower and more variable (61-77%) (34) . Nonsurgical biopsies have a yield of 60-80% and carry risks of bleeding and pneumothorax (35, 36) . Approximately one out of four surgical biopsies is performed for a benign nodule (37) .
Subsolid nodules have a higher baseline risk of malignancy than solid nodules of equal size, but are generally more indolent in their behavior when malignant. The higher probability of malignancy and less aggressive behavior inform the management algorithm for subsolid nodules. Growth in the total size of a subsolid nodule, or growth of the solid component, strongly suggests the nodule is malignant. The low metabolic activity leads to a low yield from PET imaging. Nonsurgical biopsies also have a relatively low yield (38) .
Potential clinical utility of a molecular biomarker applied to assist with the characterization of a lung nodule. A clinically useful molecular biomarker applied to the evaluation of lung nodules may lead to expedited therapy for early lung cancer and/or fewer aggressive interventions in patients with benign lung nodules.
Category of biomarker. A molecular biomarker applied to assist with the characterization of a lung nodule would be in the diagnosis biomarker category.
Potential impact of applying a molecular biomarker for lung nodule management.
d True-positive results-individuals with malignant lung nodules could be identified sooner or with fewer costly and/or invasive interventions. Definition of abbreviations: PoTP = posttest probability; PrTP = pretest probability. Assuming for a given patient that an aggressive approach will be taken if the posttest probability is greater than 65% and a surveillance approach if the posttest probability is less than 10%, the values listed in the table represent the pretest probabilities required for the stated test accuracies to impact a clinical decision if the test is positive (third column) or negative (fourth column). Trade-offs associated with lung nodule management biomarker accuracies. For the three test accuracies listed, the test is applied to a theoretical cohort of 1,000 patients with a probability of malignancy of 1, 40, and 90%. The numbers represent the impact of clinical decisions based on an interpretation of the test result as positive or negative, where positive leads to more aggressive management and negative to less aggressive management. It is assumed that for those with a probability of malignancy of 1% surveillance would have been recommended without the test, and for those with a probability of malignancy of 90% an aggressive management approach would have been advised. Black numbers suggest no change in management based on the test result. Green numbers suggest benefit, whereas red numbers suggest potentially avoidable harm. Rx = treatment. Figure 4 . Examples of study designs capable of assessing the study outcomes of interest in a trial assessing the clinical utility of a lung nodule management molecular biomarker. "Lung nodule management strategy" could be surveillance imaging at a set interval, [
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18 F]fluorodeoxyglucosepositron emission tomography imaging, nonsurgical biopsy, surgical resection, or clinician decision. Biomarker stratified: (A) Biomarker (orange circle) is measured retrospectively from prospectively collected archived samples, or is measured prospectively, but the results are not used to determine the study arm. (B) Biomarker (blue circle) is measured prospectively and the result is used to stratify patients. Both biomarker-positive and biomarker-negative patients are randomized to one of the lung nodule management strategies. Enrichment: (C) In populations with very low-risk or very high-risk lung nodules it may not be practical to randomize those in the biomarker-negative arm (for those at very low risk) or biomarker-positive arm (for those at very high risk) to a screening intervention other than standard of care for the studied population. Biomarker strategy: (D) The study population is randomized to a biomarker (blue circle)-strategy arm, where the lung nodule management strategy is based on the biomarker results, and an arm where all receive standard of care for the study population. Those in the second arm could also be randomized to different lung nodule management strategies. Alternatively, the biomarker could be measured for the entire study population but only used to determine the management strategy for a defined portion of the study population.
positive likelihood ratio, calculated using the above formula, would be as follows: sensitivity/1 2 specificity > [(1 -0.4)/0.4] 3 5 = 7.5. For example, a sensitivity of 75% and specificity of 90% (1 2 specificity = 10%) would equal 7.5.
∘ Conversely, the benefit of a true-negative result may be to avoid standard evaluation of an intermediate-risk nodule in favor of surveillance, and the harm of a false-negative result may be to delay the diagnosis of a localized lung cancer. If the cost-benefit ratio of surveillance versus evaluation of an intermediate-risk nodule is valued at 3:1 (one false-negative case to justify three true-negative controls), a calculation using the above formula would show a requirement that the specificity/(1 2 sensitivity) > [0.4/(1 -0.4)] 3 3 = 2. For example, a specificity of 40% and sensitivity of 80% (1 2 sensitivity = 20%) would equal 2.
Level of evidence required for a molecular biomarker to be considered clinically useful in the context of lung nodule management. To be considered clinically useful, a molecular biomarker used to assist with lung nodule management must lead to:
d Earlier diagnosis of malignant nodules without substantially increasing the number of procedures performed on patients with benign nodules, or d Fewer procedures for patients with benign nodules without substantially delaying the diagnosis of cancer in patients with malignant nodules.
Examples of study designs that could be used to obtain the above outcomes include the following (Figure 4 ):
d A molecular biomarker is measured retrospectively from archived samples obtained prospectively during a controlled trial of lung nodule management strategies.
d A molecular biomarker is measured prospectively during a controlled trial of lung nodule management strategies in which the biomarker result is not used to guide which lung nodule management strategy the patient is assigned to. d A molecular biomarker is measured prospectively, and the result is used to stratify patients into two arms (positive result and negative result). Patients in each arm are then randomized to one of two lung nodule management strategies.
Note: These designs can be incorporated into any controlled trial of lung nodule management strategies.
ENRICHMENT.
d A molecular biomarker is measured prospectively, and the result is used to stratify patients into two arms (positive result and negative result). Patients in one of the arms (biomarker positive or biomarker negative) are then randomized to one of two lung nodule management strategies. Patients in the other biomarker arm receive standard of care for the study population.
Note: This design may be preferred in study cohorts with very low-or very high-risk lung nodules as it may not be practical to randomize those with a negative biomarker result (in a very low-risk nodule cohort) or positive biomarker result (in a very high-risk cohort) to a nodule management strategy other than standard of care.
BIOMARKER STRATEGY.
d A prospective controlled trial in which study subjects are randomized to one of two study arms. In the first, the nodule management strategy is based on the result of a molecular biomarker. In the second, subjects could either receive standard of care for the study population or be randomized to nodule management strategies without use of the biomarker. Alternatively, the biomarker could be measured for the entire study population but only used to determine the management strategy for a defined portion of the study population.
Note: This design can be used to address whether a biomarker-driven strategy is better than a standard management strategy. It is less efficient than biomarker-stratified designs and cannot address whether the nodule management strategy is effective regardless of biomarker status.
Cost-effectiveness considerations for a biomarker used for the evaluation of lung nodules.
d The costs related to nodule evaluation may vary, based on differences in practice location, resources, clinical judgment, and patient populations. d Cost-effectiveness analyses should include a description of the study setting, costs, benefits, and how they were calculated. A sensitivity analysis is particularly important.
Conclusions
The application of molecular biomarkers to assist with the early detection of lung cancer has the potential to substantially improve our ability to select patients for lung cancer screening, and to assist with the characterization of indeterminate lung nodules. To support the application of molecular biomarkers in these clinical settings there must be evidence that the molecular biomarker leads to clinical decisions whose benefits outweigh their harms. Although it is tempting to apply novel testing based on promising discovery or validation level studies, the lung cancer community should insist on additional evidence of clinical utility before changing practice. We have described relevant considerations and have suggested standards to apply when determining whether a molecular biomarker for the early detection of lung cancer is ready for clinical use. n This official statement was prepared by an ad hoc subcommittee of the Assembly on Thoracic Oncology. 
